Search results
Showing 201 to 250 of 1371 results for patients and public
In development [GID-TA11289] Expected publication date: TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023)
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
In development [GID-HTE10044] Expected publication date: 17 December 2024
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
wk0 Scope prepared The scope defines the: disease(s) patients and technology covered by the assessment questions the guidance aims to
Interventional Procedures Advisory Committee members
Awaiting development [GID-TA11223] Expected publication date: 08 May 2024
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
Evidence summaries: unlicensed and off-label medicines – Integrated process statement
Alcohol-use disorders: diagnosis and management of physical complications (CG100)
This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.
Find out more about NICE technology appraisals advisory committee D members
or care needs. Our guidance goes beyond NHS care to cover social care and public health. Find out more about how to access treatment and...
In development [GID-TA11316] Expected publication date: 23 October 2024
This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.
View quality statements for QS68Show all sections
Sections for QS68
- Introduction
- List of quality statements
- Quality statement 1: Diagnosis of acute myocardial infarction
- Quality statement 2: Risk assessment for adults with NSTEMI or unstable angina
- Quality statement 3: Coronary angiography and PCI within 72 hours for NSTEMI or unstable angina
- Quality statement 4: Coronary angiography and PCI for adults with NSTEMI or unstable angina who are clinically unstable
- Quality statement 5: Level of consciousness and eligibility for coronary angiography and primary PCI
- Quality statement 6: Primary PCI for acute STEMI
leukaemia, at the Hammersmith Hospital in London. He treated the first UK patients to receive imatinib and continues to be closely...
working closely across all tiers of the trust to improve the delivery of safe patient care. He is also the Acute Care Common Stem...
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.
These are the main stages in the single technology appraisal (STA) process used before April 2018.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
achievement to allow dental practices to progress and demonstrate commitment to patient's dental and general wellbeing. The HLD...
Royal Wolverhampton NHS Trust established a respiratory action network for patients with chronic obstructive pulmonary disease (COPD)....
Find out what a NICE lay members does
This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
commentators. Consultee organisations include: national groups representing patients and carers bodies representing healthcare...
This quality standard covers the diagnosis and management of constipation of unknown cause in babies, children and young people (from birth to 18 years). It describes high-quality care in priority areas for improvement.
View quality statements for QS62Show all sections
Sections for QS62
- Introduction
- List of quality statements
- Quality statement 1: Assessment
- Quality statement 2: First-line treatment with laxatives
- Quality statement 3: Reviewing disimpaction therapy
- Quality statement 4: Reviewing maintenance therapy
- Quality statement 5: Written information
- Quality statement 6: Referral if no response to treatment
This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
View recommendations for NG111Show all sections
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]
In development [GID-TA10699] Expected publication date: TBC
In development [GID-TA11167] Expected publication date: 04 June 2024
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
Evidence summaries: unlicensed and off-label medicines – Interim process statement
This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.
View quality statements for QS130Show all sections
Sections for QS130
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Everything you need to know about payments and expenses for lay members on a NICE committee
Healthcare-associated infections: prevention and control in primary and community care (CG139)
This guideline covers preventing and controlling healthcare-associated infections in children, young people and adults in primary and community care settings. It provides a blueprint for the infection prevention and control precautions that should be applied by everyone involved in delivering NHS care and treatment.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS115Show all sections
Sections for QS115
- Introduction
- List of quality statements
- Quality statement 1: Valproate
- Quality statement 2: Pre-conception information
- Quality statement 3: Information for pregnant women
- Quality statement 4: Asking about mental health and wellbeing
- Quality statement 5: Comprehensive mental health assessment
- Quality statement 6: Psychological interventions
Accessing NHS care and treatment recommended by NICE
This quality standard covers assessing and managing obesity in adults, young people and children, including referral for specialist care and bariatric (weight loss) surgery. It includes people who are obese and have, or are at risk of, other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS127Show all sections
Sections for QS127
- Quality statements
- Quality statement 1: Informing people of their BMI
- Quality statement 2: Discussion on the choice of interventions
- Quality statement 3: Referring children and young people for specialist care
- Quality statement 4: Referring adults with type 2 diabetes for bariatric surgery assessment
- Quality statement 5: Referring adults for bariatric surgery assessment
- Quality statement 6: Follow-up care after bariatric surgery
- Quality statement 7: Nutritional monitoring after discharge from the bariatric surgery service
Total hip arthroplasty using the superpath approach for osteoarthritis
In development [GID-IPG10204] Expected publication date: TBC
Quality standards: process guide
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)
Evidence-based recommendations on cetuximab (Erbitux) for treating locally advanced squamous cell cancer of the head and neck in adults.
In development [GID-TA11187] Expected publication date: TBC
In development [GID-TA10505] Expected publication date: 12 June 2024
Interim process and methods for developing rapid guidelines on COVID-19 (PMG35)
This information sets out the process and methods used to develop rapid guidelines on COVID-19.
Biographies and interests register for the indicator advisory committee
Linking NICE AKI Quality Standards with Think Kidneys Resources
improving patient safety and outcomes. We have worked with many different individuals and groups including expert professionals and...
Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.